The kappa opioid receptor may be a potential tumor suppressor by regulating angiogenesis in breast cancer.

Our hypothesis proposes that activating κ-opioid receptors (KORs) may inhibit the progression of breast cancer and improve patient prognosis. Consequently, KORs may become a promising therapeutic target for breast cancer. Activating KORs induces not only analgesic efficacy comparable to μ-opioid receptors but also shows a promising antitumor effect and with fewer opioid-induced adverse effects. Based on present studies and our bioinformatics analysis of KORs, we propose that KORs can function as a tumor suppressor by inhibiting angiogenesis in human breast cancer; therefore, analgesics that mainly activate KORs would be more suitable for breast cancer patients. Copyright © 2021 Elsevier Ltd. All rights reserved.

Citation

Yumiao Shi, Jiamei Luo, Jie Tian, Qiaoqun Zou, Xiaoqiang Wang. The kappa opioid receptor may be a potential tumor suppressor by regulating angiogenesis in breast cancer. Medical hypotheses. 2021 May;150:110568

Mesh Tags

Substances

PMID: 33780776

search → result